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Abstract 
Advanced prostate cancer is an androgen-dependent disease for which the initial treatment is an androgen deprivation 
maneuver. However, some primary resistances to hormonal treatment occur with increasing incidence throughout the 
evolution of the disease. The taxanes, docetaxel and cabazitaxel, exert their action at multiple levels at the tumor cell: 
besides inhibiting the mitosis and inducing the cell death, they induce the nuclear accumulation of FOXO1, a potent 
nuclear factor that acts against the activation of androgen receptor inhibiting the transcription of AR-V7 variant 
associated with the development of resistances to abiraterone and enzalutamide. Docetaxel, as first-line therapy, and 
cabazitaxel, as second-line therapy, have demonstrated to increase the survival in castration-resistant prostate cancer. 
The results from last studies either on high-risk localized disease or on androgen-sensitive tumors demonstrate the 
increasing role of taxanes at earlier states of prostate cancer. 
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Introduction 
Prostate cancer (PC) is the most prevalent urogenital malignancy and the second most common cause 
of cancer death in men in Europe. Age-standardized incidence and mortality rates per 100,000 population 
per year are 96.0 and 19.3 in Europe and 96.8 and 15.2 in Spain, respectively [1]. 
 
After radical local therapy, either with radical prostatectomy or radiotherapy, about 30 % of patients 
develop advanced disease. Long-acting luteinizing hormone-releasing hormone (LHRH) agonists are 
currently the main form of androgen deprivation therapy (ADT). Complete or maximal androgen 
blockade (CAB or MAB) consists in the addition of an antiandrogen to a LHRH antagonist. Despite 
providing very good preliminary results, according to meta-analysis and systematic reviews, CAB 
appears to provide a small 5-year survival advantage of less than 5 % compared to monotherapy with 
LHRH agonist [2, 3]. 
 
Taxanes are currently the only cytostatic class of drugs able to prolong survival in men with metastatic 
castration-resistant PC (mCRPC). Until recently, docetaxel was the only effective agent for the treatment 
of mCRPC. Now cabazitaxel, a new taxane, has demonstrated an improvement in overall survival (OS) 
and progression-free survival (PFS) due to its ability to overcome docetaxel resistance in vitro and in 
vivo. This review aims to summarize the current role of taxanes in castration-sensitive and castration-
resistant advanced PC and their potential new active role in locally advanced and non-metastatic PC. 
Role of taxane agents in prostate cancer 
General overview 
Taxane agents play an important role in PC disease. In high-risk patients with locally advanced 
disease, docetaxel has been tested before prostatectomy with promising results [4], showing activity in 
PC. They also show activity and prolong OS in advanced non-castration-resistant PC (non-CRPC) in 
combination with ADT (docetaxel, CHAARTED study [5]), as first-line treatment in castration-resistant 
PC (CRPC) patients (docetaxel, TAX-327 study [6]) and, finally, as second-line treatment in CRPC after 
progression to docetaxel (cabazitaxel, TROPIC study [7]). 
 
Taxanes are mitotic inhibitors currently used as first- and second-line therapies for CRPC patients. 
Their mechanisms of action are multi-targeting (Fig. 1). They inhibit spindle disassembly by stabilizing 
the microtubule spindle, leading to cell cycle arrest and the disruption of many pathways, including 
ligand-dependent and ligand-independent androgen receptor (AR) nuclear translocation, which is 
mediated by microtubules [8]. Taxanes also induce the nuclear accumulation of FOXO1, a potent AR-
suppressive nuclear factor that has been shown to inhibit the transcription of AR-V7 [8], a prevalent AR 
splice variant associated with enzalutamide and abiraterone resistance. In fact, detection of AR-V7 in 
circulating tumor cells from men with CRPC is not associated with primary resistance to taxanes. 
Therefore, AR-V7 may potentially serve as a treatment-selection marker in CRPC patients [9]. 
 
  
 
 
 
Fig. 1. Mode of action of cabazitaxel (Cbz): a normal tumoral cell; b Cbz action on the tumoral cell at three levels: 1 at 
microtubules as cytotoxic; 2 at RA impeding its translocation to nucleus; 3 at the nucleus, increasing the FOXO1 concentration 
It is already known that PC is highly heterogeneous with the coexistence of AR-positive and AR-
negative cancer cells in most patients, the latter being chemo-responsive. Targeting AR-positive cancer 
cells with endocrine therapies induces the clonal proliferation of AR-negative and AR-independent 
metastases [10]. There is growing evidence that differentiation to an AR-negative phenotype is a 
mechanism of resistance to AR pathway-targeted therapy leading to neuroendocrine differentiation [11]. 
Endocrine therapies can promote paradoxical tumor proliferation and lethal tumor phenotypes in patients 
with retinoblastoma loss or inactivation, a finding reported in 25–50 % of cases of PC [12, 13]. 
 
Increased expression of N-cadherin in PC biopsies has been observed as early as 3 months after 
initiation of ADT and has been associated with loss of AR expression, epithelial-mesenchymal transition, 
cancer invasion and metastasis. Other mechanisms of resistance to AR-targeted agents include mutation, 
the generation of splice variants, and glucocorticoid receptor overexpression, which also possibly 
contribute to the induction of aggressive disease [14]. The specific role of taxanes in the different 
scenarios of advanced PC is reviewed here. 
Taxanes (docetaxel) in combination with radiotherapy, ADT and zoledronic acid in high-risk locally 
advanced or metastatic PC 
In locally advanced PC, docetaxel has shown activity in the RTOG 0521 study (in combination with 
radiotherapy) [15] and in the STAMPEDE study [16], both presented at 2015 ASCO congress. The 
STAMPEDE study [16] recruited men with high-risk locally advanced or metastatic PC starting hormone 
therapy. A total of 2962 patients were randomly allocated 2:1:1:1 to hormone therapy, hormone therapy 
plus docetaxel, hormone therapy plus zoledronic acid, and hormone therapy plus docetaxel plus 
zoledronic acid. In high-risk locally advanced patients, a statistically significant improvement in failure-
free survival was observed from adding docetaxel to hormone therapy, but not in OS, may be due to the 
fact that the number of events is still very small. In the RTOG 0521 study [15] high-risk, localized PC 
patients benefited from adjuvant docetaxel which improved the OS from 89 to 93 % at 4 years. Both 
studies reinforce the importance and the central role of taxanes-based chemotherapy in this disease at 
earlier states. 
  
Taxanes (docetaxel) in combination with ADT in non-castration-resistant prostate cancer (non-CRPC) 
The combination of ADT and chemotherapy in advanced non-CRPC is under debate. Attacking the de 
novo testosterone-independent cells with chemotherapy early is an argument in favor of the use of this 
combination. An argument against this approach is the fact that some patients will never need 
chemotherapy, sparing the associated toxicity. 
 
In the CHAARTED study (E3805) [5], the results from non-CRPC patients, who were randomized to 
receive ADT either continuously alone or combined with six cycles of docetaxel at standard dose, were 
presented at the 2014 ASCO meeting. A median OS of 44 months for ADT-treated patients was obtained, 
compared to 57.6 months for chemotherapy plus ADT-treated patients [HR = 0.61 (95 % CI: 0.47–0.80); 
p = 0.003]. This difference was even higher in high-volume metastatic patients (32.9 vs. 49.2 months; 
HR = 0.6; p = 0.006). The authors concluded that six cycles of chemotherapy in addition to ADT 
represent an appropriate option for men with metastatic PC who are suitable for docetaxel therapy. Men 
with high-volume ADT-naive metastatic disease should be considered for ADT plus docetaxel based on 
the results of the E3805 CHAARTED study [17]. The STAMPEDE trial [16] included patients with 
newly diagnosed metastatic PC that was node positive, high-risk locally advanced or relapsing after 
previous radical local therapy. The patients were randomized to standard of care hormonal therapy plus 
docetaxel, zoledronic acid or both. Regarding M1 patients, the difference in OS between patients treated 
with ADT + docetaxel and the control arm was 22 months (p = 0.002). It is important to emphasize that in 
the STAMPEDE trial no differences were made between low and high-volume disease, raising the issue 
of whether should all patients receive docetaxel, irrespective of the volume or the risk of the disease, or 
not. 
 
In a previous study, the GETUG-AFU 15 study [18], chemotherapy and hormone therapy combination 
prolonged disease-free survival (DFS) in comparison to ADT but did not show any survival advantage in 
non-CRPC patients. Indeed, this study was much smaller than E3805, and the number of patients in the 
ADT-only arm who received docetaxel for disease progression was 31 % in the E3805 study and 62 % in 
the GETUG-AFU 15 study. Interestingly, the patients in the ADT-only arm received docetaxel during 
post-progression treatment, raising the issue of the best timing of chemotherapy administration. Finally, 
GETUG-AFU 15 also had much fewer high-volume disease patients (22 % compared to 66.2 % in 
E3805) and the number of cycles of docetaxel in the combination arm was higher than in the 
CHAARTED study. 
 
In conclusion, the use of docetaxel should be considered in men with newly diagnosed metastatic or 
high-risk locally advanced disease if they are fit to receive chemotherapy. 
Taxanes (docetaxel) in symptomatic metastatic castration-resistant prostate cancer (mCRPC) 
CRPC must be defined before we proceed to define the role of docetaxel in this context. According to 
the European Association of Urology (EAU), an accurate definition of CRPC must meet the following 
criteria [19]: castrate serum testosterone levels, three consecutive increases in prostate-specific antigen 
(PSA), resulting in two 50 % increases above the nadir, antiandrogen withdrawal for at least 4 weeks, 
PSA progression despite secondary hormonal manipulations and/or progression of bone (at least two new 
lesions upon bone scan) or soft tissue (RECIST criteria) lesions. Patients with mCRPC have a poor 
prognosis and a life expectancy of around 18–19 months. 
 
M0 CRPC is characterized by the absence of visceral, skeletal, lymphatic and soft tissue metastasis 
detected by bone scan, computed tomography (CT) or magnetic resonance imaging (MRI), although the 
development of new and better imaging techniques (PET) will enable earlier detection of possible 
metastatic lesions. There is no treatment of choice for M0 CRPC patients, and their inclusion in clinical 
studies is encouraged. 
  
In M1 CRPC, two types of patients are defined: symptomatic or asymptomatic/mildly symptomatic. 
For symptomatic patients, chemotherapy is the treatment of choice; hormone therapy based on 
abiraterone (COU-AA-302 study) [20] or enzalutamide (PREVAIL study) [21] may be considered for 
those with few or no symptoms; however, docetaxel also seems to be active in asymptomatic or mildly 
symptomatic patients. 
 
The first chemotherapy drug to demonstrate activity in CRPC a disease considered classically 
chemoresistant was mitoxantrone: in combination with prednisone, this drug showed a significant benefit 
in patients in terms of pain relief (29 vs. 12 %, p = 0.001) and duration of symptomatic response (43 vs. 
18 weeks, p < 0.0001), but had no impact on OS [22]. This combination of mitoxantrone and prednisone 
was the chemotherapy of choice for CRPC patients until 2004, when the results of two phase three studies 
demonstrated the superiority of docetaxel with prednisone over the mitoxantrone regimen. The most 
important of these two studies was the so-called TAX327 study, which randomized 1006 patients to 
receive either docetaxel 75 mg/m
2
 every 21 days, weekly docetaxel 30 mg/m
2
 or mitoxantrone 12 mg/m
2
 
every 21 days; in all three arms, prednisone 5 mg was also administered every 12 h. The group of patients 
who received tri-weekly docetaxel had their risk of death reduced by 24 % compared to the mitoxantrone 
arm, with a median survival rate of 18.9 and 16.5 months, respectively (HR = 0.76, p = 0.009); pain was 
also significantly improved in the group receiving docetaxel every 3 weeks (35 vs. 22 %, p = 0.01) as was 
quality of life (22 vs. 13 %, p = 0.009) compared to the patients receiving mitoxantrone [6]. 
 
Therefore, the regimen containing docetaxel 75 mg/m
2
 every 3 weeks in combination with prednisone 
5 mg every 12 h became the treatment of choice for patients with symptomatic CRPC. These favorable 
tri-weekly docetaxel data were confirmed in an update in 2008, with a median survival 19.2 vs. 
16.3 months (HR = 0.79, p = 0.004) and a 5 % increase in survival at 3 years (18.6 vs. 13.5 %) [23]. In 
the subgroup analysis, we found that patients with visceral involvement and symptomatic patients with a 
Karnofsky score of less than 90 % or with elevated PSA levels (greater than 114 ng/ml) had worse 
outcomes. Specifically, it should be noted that symptomatic patients had a median survival rate of 17.1 vs 
25.9 months for those with minimal symptoms. Interestingly, docetaxel is also superior to mitoxantrone 
in these symptomatic patients. 
 
Regarding PSA response, it is interesting to note that, in the majority of patients, this was associated 
with an improvement in quality of life and alleviation of pain; in turn, the combination of biochemical 
response and decreased pain was associated with a significant improvement in survival [23]. Moreover, 
for patients unlikely to tolerate this 3-weekly regimen due to the presence of comorbidities, 50 mg/m
2
 
docetaxel administered every 2 weeks could be a useful option [24]. 
Taxanes (docetaxel) in asymptomatic or mildly symptomatic patients with CRPC 
Besides the presence of symptoms, there are no well-defined predictive factors to determine which 
asymptomatic or mildly symptomatic patients would benefit from docetaxel-based chemotherapy over 
hormonal maneuvers, including abiraterone or enzalutamide. There are general factors that predict rapidly 
progressive disease and shorter survival and justify the choice of docetaxel as first-line treatment: the 
presence of anemia, multiple metastatic sites, elevated LDH and alkaline phosphatase levels and 
specifically PSA doubling time (PSADT) of less than 55 days, in accordance with the international 
consensus. 
 
Mildly symptomatic patients in whom chemotherapy may be preferred are those asymptomatic 
patients included in the COU-AA-302 study treated with abiraterone [20] and having a poor outcome. 
Docetaxel-based chemotherapy may also be considered in patients with anemia, elevated LDH levels, an 
elevated PSA doubling time value or the presence of lymph nodes plus visceral disease, as patients with 
visceral metastases were excluded from the COU-AA-302 study. 
  
Taxanes (cabazitaxel) after docetaxel progression 
Four options with category 1 recommendations are now available after progression to docetaxel, 
including a cytostatic agent (cabazitaxel), two hormonal treatments (abiraterone and enzalutamide) and a 
radio-transmitter alpha particle (radium-223). There is no drug of choice because none of these treatments 
have been compared to one another, and the selection of therapy is currently based primarily on clinical 
characteristics such as previous therapy, the presence of visceral metastases or disease symptoms, adverse 
event profiles, life expectancy, comorbidities, performance status, cost and patient preference. A fifth 
option is retreatment with docetaxel in patients who have previously responded to this taxane; however, 
evidence supporting this option is not robust (phase 2 retrospective studies with a small number of 
patients) and has not, in any case, been shown to increase survival [25]. 
 
Cabazitaxel is a new generation taxane specifically designed to overcome docetaxel-generated 
resistance. Interestingly, this agent easily crosses the blood–brain barrier. Cabazitaxel was compared to 
mitoxantrone following docetaxel progression in the randomized, multicentre, international phase 3 
TROPIC study [7]; this study compared cabazitaxel at a dose of 25 mg/m
2
 and mitoxantrone at a dose of 
12 mg/m
2
 every 3 weeks; this was combined with 10 mg of prednisone daily in both arms. Seven hundred 
and fifty-five ECOG 0-2 patients with CRPC, who had progressed during or after at least three cycles of 
docetaxel, were randomized to receive cabazitaxel (n = 378) or mitoxantrone (n = 377) until disease 
progression or unacceptable toxicity or for a maximum of ten cycles. Stratification was performed by 
ECOG 0-1 vs. 2 and measurable vs. non-measurable disease. The primary endpoint was OS; secondary 
endpoints included PFS, defined as the time between the date of randomization and PSA progression, 
tumor progression, increased symptoms or death. 
 
The median survival of patients in the cabazitaxel arm was 15.1 months, whereas that in the 
mitoxantrone arm was 12.7 months. This difference translates into a reduction in the risk of death of 30 % 
for patients receiving cabazitaxel (HR = 0.70, 95 % CI: 0.95–0.83, p < 0.0001); median PFS was 
2.8 months for cabazitaxel (95 % CI: 2.4–3.0) and 1.4 months for mitoxantrone (95 % CI: 1.4–1.7). With 
a median follow-up of 25.5 months, data confirmed that the 2-year survival rate was higher in patients 
treated with cabazitaxel [26]. Cabazitaxel also prolonged survival in comparison to mitoxantrone 
independently of the number of poor prognostic factors, including visceral disease [27]. Interestingly, the 
absolute benefit of cabazitaxel in the TROPIC study is of the same magnitude of docetaxel in the TAX 
327 study, but the population was older, had received more treatment, and had received a taxane 
previously [26]. These results show that treatment with cabazitaxel significantly improves survival in 
patients with aggressive disease compared to mitoxantrone-prednisone (MP), including patients with 
visceral metastases. 
 
The most common toxicities with cabazitaxel were neutropenia (primary prophylaxis was not 
allowed) and diarrhea; 28 % of patients treated with cabazitaxel had febrile neutropenia, so it is 
considered advisable to assess the prophylactic use of hematopoietic growth factors under the following 
circumstances: patients aged more than 65 years old, which had been treated with radiotherapy or present 
with extensive bone disease or had prior history of febrile neutropenia with docetaxel. It is important to 
point out that it is safe for elderly patients to receive cabazitaxel taking into account that they are fit for 
chemotherapy [28]. In this regard, there is an ongoing study that focuses on the tolerability and efficacy 
of weekly cabazitaxel in unfit CRPC patients who progressed to docetaxel [29]. It is important to 
emphasize, as has already been mentioned, that, in relation to the cabazitaxel hematological toxicity 
which occurred in the TROPIC study, the use of primary prophylaxis with colony-stimulating factors was 
not permitted; however, with its more frequent use in daily clinical practice, the incidence of neutropenia 
has decreased notably [30]. 
 
The decision to start treatment with cabazitaxel after docetaxel progression should be based on 
individual patient characteristics in the absence of formal comparison to the alternative of hormonal 
treatment, either with abiraterone or enzalutamide. Refractoriness or early progression to docetaxel could 
be one argument for the indication of cabazitaxel, among others, as will be discussed later. 
  
Phase 3 studies underway with cabazitaxel in CRPC 
The PROSELICA study (NCT01308580) comparing the administration of cabazitaxel at doses of 20 
vs. 25 mg/m
2
 in CRPC patients who progressed to docetaxel is ongoing. The main endpoint is OS and the 
secondary endpoints are: safety, PFS, progression by PSA and tumor size, as well as pain or quality of 
life responses. 
 
Another study is testing the value of front-line cabazitaxel in a phase 3 study called FIRSTANA 
(NCT01308567), which is comparing cabazitaxel tri-weekly at a dose of 25 vs. 20 mg/m
2
 with a standard 
docetaxel 75 mg/m
2
 regimen every 3 weeks. In all three arms, prednisone 10 mg daily is also 
administered. The primary endpoint is OS and secondary endpoints are PFS, radiographic PFS, tumor 
response in measurable disease, PSA responses, PFS biochemistry, pain control, time to development of 
skeletal complications and quality of life. 
 
The third phase 3 study which has been launched concerns cabazitaxel in combination with 
prednisone with or without the anti-clusterin agent custirsen (NCT015788655) as second-line therapy, 
which aims to explore the activity and safety of cabazitaxel in combination. 
Profile of candidate patients for cabazitaxel therapy 
An analysis of the characteristics of the patients recruited into the TROPIC study [7], which could 
guide us in selecting an appropriate profile for cabazitaxel patients, revealed that 25 % had visceral 
metastases, 92.6 % had a performance status of ECOG 0-1, 30 % had undergone two or more prior 
chemotherapy regimens, including docetaxel at different dose levels, and more than 70 % were refractory 
to docetaxel (progression during or within 3 months of docetaxel completion). 
 
Basically, the type of patients to be treated with cabazitaxel would include those with mCRPC and 
suspected hormonal independence, especially those with more aggressive potential (Gleason > 7), rapid 
progression to mCRPC with primary ADT, and those who are clearly refractory to docetaxel, particularly 
if progression has occurred during treatment with this drug. Patients aged ≥70 years showed similar 
general and hematological toxicity compared to patients below 70 years of age. Prior treatment with 
ketoconazole and baseline serum adrenal androgen levels may also have to be taken into account. 
However, this should not exclude patients with less aggressive clinical disease who, as we have seen, also 
benefit from treatment with cabazitaxel. 
 
Finally, we cannot forget that, of all four therapeutic options after docetaxel progression, the 
cabazitaxel option requires the patient to have a good ECOG score to be used safely. This means that 
cabazitaxel must be used in the setting of the disease in which the patient maintains a performance status 
sufficient to receive a potentially toxic chemotherapy agent. 
Taxanes (cabazitaxel) as part of the sequential treatment in CRPC after docetaxel progression 
As already mentioned, in addition to cabazitaxel, there are a range of options available after 
progression to docetaxel, including two hormonal treatments (abiraterone and enzalutamide) and a radio-
transmitter alpha particle (radium-223). All of these treatments are valid options, taking into account the 
characteristics of the patients and the drug availability. As we know, there is no drug of choice because 
none of these treatments have been compared head-to-head with one another. It is not yet known how 
great the incremental benefit obtained through the sequential use of the novel treatments will be. As a 
consequence, no specific sequence of post-docetaxel treatment can be recommended. Interestingly, as is 
the case with other common advanced tumors, the more drugs used, the better the outcome: using 
cabazitaxel and abiraterone–enzalutamide after progression to docetaxel, whatever the sequence of 
administration is used, is associated with longer survival than the use of just two of these drugs [31]. 
  
Sequence of treatment after docetaxel progression: cabazitaxel and new hormonal therapies 
In a retrospective study of 113 patients progressing after docetaxel treatment, a better outcome was 
obtained by more patients receiving the cabazitaxel–abiraterone sequence than those receiving the 
abiraterone–cabazitaxel sequence; this included a lower risk of mortality [32]. 
 
In another retrospective study of CRPC patients having progressed after first-line treatment with 
docetaxel, 63 patients received cabazitaxel and then abiraterone and 69 patients received abiraterone and 
then cabazitaxel. Median OS was 19.1 and 17.0 months in the cabazitaxel–abiraterone sequence and 
abiraterone–cabazitaxel sequence, respectively (p = 0.36); median PFS and biochemical PFS were 
significantly longer in the cabazitaxel–abiraterone sequence vs. the opposite: 8.1 vs. 6.5 months 
(p = 0.050) and 9.5 vs. 7.7 months (p = 0.024), respectively. Minor differences in toxicity were observed 
based on therapy sequence; generally, toxicity from cabazitaxel could be severe, while abiraterone 
toxicity was milder. The authors concluded that patient survival did not differ significantly based on 
treatment sequence and that primary progression on cabazitaxel or abiraterone did not preclude a response 
to the other agent in CRPC patients. However, tumor response to both agents, particularly cabazitaxel, 
was lower when administered as later-line therapy in the selected study population [33]. 
 
Finally, Maines published data from 13 retrospective trials with 1016 patients, that included the 
following sequences in post-docetaxel setting: new hormonal therapy (NHA) → NHA (469 patients); 
NHA → cabazitaxel (318 patients); and cabazitaxel → NHA (229 patients). The 12-month OS rates in the 
three sequence groups were 28.5, 61.3, and 76.4 %, respectively. Data concerning major prognostic 
factors (median age, PS ECOG 0-1 and >2, Gleason score >8 and the rate of bone, lymph nodes and 
visceral metastases) in the three groups were no substantially different between them. Despite the 
retrospective nature of the data, possible survival advantage could be observed when Cabazitaxel-based 
sequence is used [34]. 
Are taxanes still active after abiraterone or enzalutamide? 
There are limited clinical and pre-clinical data to suggest the existence of cross-resistance between 
docetaxel and enzalutamide or abiraterone. In vitro studies indicate that taxanes may act by disrupting AR 
signaling. This may represent a potential mechanism for cross-resistance in mCRPC among taxanes and 
new hormonal agents [8]. However, taxanes also induce cell death by means of AR-independent 
mechanisms that may overcome prior hormone-therapy resistance and act against AR-negative cells. 
Docetaxel 
The efficacy of docetaxel remains controversial after abiraterone use according to various 
retrospective studies. In a retrospective study of docetaxel efficacy, in 35 out of 54 mCRPC patients 
previously treated with abiraterone [35], no responses to docetaxel were seen in patients who did not 
attain a PSA decline ≥50 % with abiraterone; docetaxel only resulted in 26 % PSA response rate, a 
median time to PSA progression of 4.6 months and median OS of 12.5 months. In this study, the eight 
abiraterone-refractory patients were also refractory to docetaxel. 
 
A more recent study [36] had the same results, indicating a cross-reaction between docetaxel and 
abiraterone; however, PSA responses were reported with docetaxel in patients who did not achieve a PSA 
decline ≥50 % with abiraterone. In a third study [37], the outcomes of 86 mCRPC patients treated with 
docetaxel after abiraterone were studied; the authors found that confirmed PSA response rates, median 
PFS and median OS with docetaxel did not significantly differ between patients who experienced no PSA 
decline, <50 % decline and ≥50 % decline with abiraterone. In the cohort of 54 patients with abiraterone-
refractory disease, the confirmed PSA response rate was 37 %. These data are comparable to the findings 
of Schweizer et al. [36], who observed PSA responses in 39 % (7/18) of abiraterone-refractory patients. 
  
In summary, in the first study, no responses to docetaxel were seen in patients who did not attain a 
PSA decline ≥50 % with abiraterone [35]; in the second study [36], PSA responses to docetaxel were 
reported in patients who did not achieve a PSA decline ≥50 % with abiraterone; and, finally, in the third 
study, [37] PSA response rates, median PFS and median OS with docetaxel did not significantly differ 
between patients who experienced no PSA decline, <50 % decline and ≥50 % decline with abiraterone. 
 
Globally, we found that docetaxel efficacy in mCRPC patients was not clearly linked to the 
biochemical response to previous abiraterone therapy. In the absence of prospective studies, our data 
suggest that biochemical response to prior abiraterone therapy should not be used to guide patient 
selection for subsequent treatment with docetaxel. 
Cabazitaxel 
The influence of AR-targeted agents on the activity of cabazitaxel, a next-generation taxane developed 
to overcome docetaxel resistance, remains controversial. 
 
In one study, the activity of cabazitaxel in CRPC after docetaxel and the novel endocrine agents, 
abiraterone and enzalutamide, was measured; 59 patients were treated with cabazitaxel, 37 of whom had 
previously received abiraterone and 9 of whom had previously received enzalutamide. These patients 
received a median of 7 months of abiraterone and 11 months of enzalutamide. A median of six 
cabazitaxel cycles were delivered with ≥50 % PSA declines in 39 %, soft tissue radiological responses in 
14 % and symptomatic benefit in 24 %. Median OS and PFS were 15.8 and 4.6 months, respectively. The 
authors concluded that cabazitaxel showed a significant activity in patients who had already been treated 
with docetaxel, abiraterone and enzalutamide [38]. 
 
Another group reviews their data relating to 132 consecutive patients treated with cabazitaxel after 
docetaxel progression; they found that patients receiving AR-targeted agents after cabazitaxel 
demonstrated a twofold improvement in radiological and clinical progression and OS compared to those 
receiving AR-targeted agents before cabazitaxel, despite similar PSA response rates [39]. 
 
In a similar study, 79 patients who had progressed after docetaxel and abiraterone received cabazitaxel 
25 mg/m
2
 every 3 weeks. A PSA decline ≥30 % was achieved in 48 patients (62 %; 95 % CI: 51–73) and 
a PSA decline >50 % was achieved in 35 % (95 % CI: 25–47). The authors concluded that cabazitaxel 
and AR pathway inhibitors are not cross-resistant due to the fact that cabazitaxel does not act mainly 
through AR axis inhibition [40]. 
 
Taken together, these data suggest that cabazitaxel is an effective taxane in patients with mCRPC, as 
well as in pre-clinical models that are resistant to AR-targeted agents. As a consequence, we can conclude 
that there is a lack of cross-resistance between cabazitaxel and AR-targeted agents, because cabazitaxel 
acts mainly through AR-independent mechanisms. In an enzalutamide-resistant xenograft model, 
cabazitaxel was associated with a similar PSA response but greater anti-tumor activity and prolonged PFS 
when compared to docetaxel [41]. We should feel reassured by the existence of an active agent that is 
able to prolong survival in patients progressing on new AR-targeted agents. 
 
In the current treatment landscape, with healthcare expenditure increasing exponentially, we should 
stop thinking that one specific AR-targeted agent is good for all the patients because it is easy to use and 
well tolerated. Some patients do not respond to these drugs and stimulation of the clonal component of 
the disease might render the tumor even more aggressive and reduce the patient’s chances of survival. 
 
At last, prospective randomized studies are needed to unambiguously confirm the existence of cross-
resistance between AR-targeted agents and determine which sequence of therapies would be most 
beneficial to men with mCRPC. 
  
It can be concluded that the true impact of sequential therapy is not yet established; however, based on 
limited clinical data, sequential treatment with cabazitaxel, abiraterone and enzalutamide has shown 
clinical activity and should be considered in patients with mCRPC [32]. 
Conclusions 
In recent years, the therapeutic scenario of advanced PC has changed dramatically. Taxanes play a 
central role in this new era of PC treatment. Besides docetaxel, we can use now cabazitaxel as second-line 
treatment of mCRPC, with studies concerning its use as first-line treatment ongoing. Moreover, the role 
of taxanes has been reinforced with the presentation in the 2014 ASCO congress of the CHAARTED 
study results, which demonstrate the importance of docetaxel in combination with ADT in patients with 
non-CRPC. Moreover, two recent studies presented at the 2015 ASCO congress—the STAMPEDE and 
the RTOG 0521 studies—have reinforced the value of taxane-based chemotherapy at the earlier states of 
the PC. The ultimate goal of all cancer therapies is to prolong patient survival and improve quality of life. 
In patients with CRPC, docetaxel and cabazitaxel achieve these two objectives. Actually, the current 
SEOM (Sociedad Española de Oncología Médica) [42] and ESMO (European Society of Medical 
Oncology) [43] clinical guidelines reflect the importance of taxanes in prostate cancer treatment. We can 
conclude that taxanes (docetaxel and cabazitaxel) are essential agents in the management of advanced PC. 
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